|
Sep 26
|
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
|
|
Jun 10
|
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
|
|
May 13
|
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
|
|
Apr 24
|
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
|
|
Apr 23
|
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
|
|
Apr 22
|
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
|
|
Mar 28
|
Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results
|
|
Mar 28
|
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
|
|
Mar 27
|
Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares
|
|
Mar 12
|
Private equity firms who have a significant stake must be disappointed along with institutions after Centessa Pharmaceuticals plc's (NASDAQ:CNTA) market cap dropped by US$139m
|
|
Feb 22
|
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
|
|
Dec 27
|
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics
|
|
Dec 26
|
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
|
|
Dec 10
|
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
|
|
Dec 5
|
Does Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) Have the Potential to Rally 40.85% as Wall Street Analysts Expect?
|
|
Nov 27
|
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
|
|
Nov 13
|
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
|
|
Nov 2
|
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
|
|
Sep 4
|
Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why
|
|
Jul 10
|
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors
|